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ABSTRACT
Objective: To examine the economic impact of patients
with anemia in selected diseases.
Methods: A retrospective cohort design was used to esti-
mate the differences in costs between anemic and nonane-
mic patients. The analysis used administrative claims data
(1999–2001) from a US population to assess direct costs
and disability and productivity data (1997–2001) to esti-
mate indirect costs. Adult patients with a diagnosis of
rheumatoid arthritis (RA), inﬂammatory bowel disease
(IBD), chronic obstructive pulmonary disease (COPD),
chronic kidney disease (CKD), cancer, or congestive heart
failure (CHF) were identiﬁed. Costs were estimated using
a generalized linear model, adjusting for age, sex, comor-
bidities, and disease severity. The adjustment variables for
disease severity were based on ICD-9, HCPCS, or phar-
macy codes. These costs were projected to a 1-million-
member, similar population.
Results: The percentage of anemia patients varied among
conditions (6.9–26.1%); the CKD population had the
highest prevalence. CKD anemic patients incurred the
greatest average annual direct costs ($78,209), followed
by CHF ($72,078) and cancer ($60,447). After adjusting
for baseline characteristics including severity, the differ-
ence in direct costs between anemic and nonanemic
patients decreased for all diseases; CHF patients incurred
the greatest adjusted cost difference between anemic and
nonanemic ($29,511), followed by CKD ($20,529) and
cancer ($18,418). Unmeasured severity and coding bias
may account for a portion of the differences in the
adjusted cost.
Conclusion: Anemia may substantially increase health-
care costs at a level that is economically very relevant,
despite the fact that these patients may comprise only one
tenth of the overall anemic population.
Keywords: anemia, comorbid conditions, economics,
indirect costs.
Introduction
Anemia occurs commonly. Self-report data from the
National Center for Health Statistics revealed that
approximately 3.4 million individuals have anemia
in the United States [1]. The second National
Health and Nutrition Survey (NHANES) reported
anemia to be most prevalent in infants (5.7%), teen-
age girls (5.9%), young women (5.8%), and elderly
men (4.4%) [2]. The likelihood of anemia is even
greater in patients with chronic conditions. In pre-
vious studies, anemia of chronic disease has been
identiﬁed in 36% of patients with chronic kidney
disease (CKD) [3], and 27% of patients with rheu-
matoid arthritis (RA) [4]. The increasing amount of
literature on the prevalence of anemia within such
diseases provides further evidence that it is a condi-
tion of growing concern [5–8]. Nevertheless, prior
work on anemia has primarily focused on preva-
lence rates in the general population whereas the
economic importance and ﬁnancial impact of this
disease has been overlooked. Published literature on
the impact of anemia within chronic diseases has
been limited and the economic burden of this con-
dition on a population remains unknown. Even
national publications such as Healthy People 2010
put limited focus on anemia, by placing little atten-
tion on its effect and consequences [9].
The current study examines the economic impact
of patients with anemia in a managed care popula-
tion. Health-care costs (direct and indirect medical
costs) were compared between anemic and nonane-
mic patients with any one of the following diseases
known to have a high prevalence associated with
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anemia [2–5]: RA, inﬂammatory bowel disease
(IBD), chronic obstructive pulmonary disease
(COPD), CKD, cancer, or congestive heart failure
(CHF). The data show a sizable economic burden
associated with anemia both on an individual and a
population level.
Methods
This study used a retrospective cohort design to
estimate the impact of anemia on health-care costs
in selected diseases. A cross-sectional comparison of
direct and indirect costs between anemic and non-
anemic populations was examined. Although the
model addressed differences in current costs be-
tween anemia and nonanemia populations, it did
not predict future costs.
The analysis used administrative claims data
from the Medstat Group’s 1999–2001 MarketScan
Commercial Claims and Encounters Database to
assess direct costs and the 1997–2001 Health and
Productivity Management Database to estimate
indirect costs. The MarketScan Commercial Claims
and Encounters Database includes (inpatient and
outpatient service) claims from employers, health
plans, and government organizations for more than
11 million covered lives in the United States
whereas the Health and Productivity Management
Database contains data from seven large employers
with ofﬁces in 43 states in the United States, repre-
senting more than 800,000 covered lives (employees
and dependents). The database for indirect costs
included both absenteeism and short-term disability
(STD) data. The absenteeism database contained
detailed information about each employee’s absence
from work. Relevant information abstracted for the
analysis included hours missed from work, dates of
the absence, and the reason for the absence.
Absence claims were also linked to medical claims
data. The STD data provided information for each
employee’s disability. Data on the ﬁrst day missed
from work, the date returned to work, and the pay-
ments for the claim were applicable to the analysis.
Because the Health and Productivity Management
database is relatively small compared with the
Commercial Claims database, disease prevalence
rates were based on the population from the latter
database.
Study Sample
Continuously enrolled adult patients (age ≥
18 years) diagnosed with any of the six conditions
of interest (RA, IBD, COPD, CKD, cancer, or CHF)
were identiﬁed. Patients met the continuously
enrolled criteria if there was no break in days of
enrollment. These conditions were selected because
the literature has shown a high prevalence of ane-
mia associated with each [6–11]. Patients were
included in the study if at least one of the following
conditions was met: 1) one or more hospital admis-
sions for the condition with the diagnosis appearing
in any position; 2) one or more emergency room
(ER) visits for the condition with the diagnosis as
the ﬁrst-listed (primary) diagnosis; or 3) two or
more outpatient visits at least 30 days apart, both
having the diagnosis of interest. Patients with CKD
on dialysis were considered to be a complex group
where the relationship between the underlying con-
dition, anemia, and associated costs were very dif-
ﬁcult to separate. In an effort to not overestimate
the independent impact of anemia, these patients
were therefore excluded from the analysis.
On identifying patients that met the criteria for
the condition of interest, patients were grouped into
anemia and nonanemia categories within each con-
dition. This study focused on prevalent cases of ane-
mia, rather than just incident or new cases. Anemia
patients were identiﬁed as individuals meeting any
of the following criteria: 1) one diagnosis of anemia
on a hospital or ER claim; or 2) one diagnosis of
anemia on a professional claim (i.e., ofﬁce visit) if
there was also evidence that a hematocrit, hemo-
globin, or complete blood count was performed on
any date before the date of the visit. The ICD-9
codes used to identify anemia included iron deﬁ-
ciency anemia (280.x), anemia in chronic illness
(285.2x), other nutritional anemia (281.9), anemia,
unspeciﬁed (285.9), and other speciﬁed aplastic
anemia (284.8). In addition, ICD-9 procedure codes
(v-codes), CPT-4, and HCPCS codes for transfusion
were used. These included ICD-9 CM: V58.2,
V99.0x, CPT-4: 36430, 36440, 96400–96549, and
HCPCS: P9010–P9013, P9016–P9023. Actual lab-
oratory values were not available to verify the pres-
ence or severity of anemia.
It was expected that some patients would have
more than one of the six conditions of interest. For
estimates of condition and anemia prevalence, to
avoid double counting, patients with multiple con-
ditions were only placed into the single condition
with the greatest direct cost due to anemia. For
determining the cost of each condition, patients
could be included in more than one analytic data set
(e.g., a patient with RA and cancer was analyzed in
the RA group as well as the cancer group). All
dependent variables (outcome measures) and inde-
pendent variables were evaluated for a 1-year obser-
vation period, as further described below.
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Outcome Measures
Direct health-care costs and indirect costs due to
loss of productivity and STD were the dependent
variables used in the regression models (as described
later in this paper). Direct costs (from the health
plan perspective) included payments for inpatient
hospital, ER, outpatient hospital, physician ofﬁce
visits, and pharmacy. Indirect costs included absen-
teeism and STD. Mean annual expenditures of ane-
mia and nonanemia patients were calculated for
direct and indirect costs. The cost of absenteeism
was evaluated by multiplying hours absent by
$23.15, the average wage estimated by the Bureau
of Labor Statistics [12]. The cost of STD was
derived directly from the data ﬁeld for payment in
the data. If payment for STD was not provided,
then the cost was evaluated by multiplying the
number of STD days by $111.12. This value was
calculated as 60% of the estimated value of a day of
work under the assumption that a typical STD pro-
gram beneﬁt compensates for 60% of an employee’s
pay and beneﬁts.
Adjustment for Disease Severity
Anemic patients often have higher disease severity.
In an effort to partially account for costs due to
severity of a disease rather than the condition of
anemia, a variable adjusting for disease severity was
created for each of the six conditions. Patients were
categorized into mild, moderate, and severe catego-
ries based on speciﬁc ICD-9 codes, HCPCS codes
for durable medical equipment, or pharmacy codes
(Appendix 1). As an example, severity adjustment
for cancer was based on whether patients were
actively receiving chemotherapy (moderate) or had
evidence of metastasis (severe). CKD severity placed
patients who had one hospitalization for CKD dur-
ing the observation period in the moderate category
while placing those who had more than one CKD
hospitalization or kidney transplantation in the
severe category. Severity for RA was primarily
based on medications and surgery; biologic thera-
pies and some nonbiologic therapies were an indi-
cator of moderate RA, although joint surgery was
an indicator of late stage, or severe, RA. IBD sever-
ity was based on medication, hospitalization, and
surgery; more advanced medications, surgery, or
multiple hospitalizations were an indicator of severe
IBD. For CHF, the severity increased as the number
of concomitant CHF medications and hospitaliza-
tions increased. In practice, physicians would add
on different classes of CHF medications as the
severity increases. Thus, the criterion of concomi-
tant medications from different classes was applied
to improve the ability of identifying different sever-
ity levels of CHF than just hospitalization alone.
Unlike other diseases, staging for COPD was deter-
mined in part by the use of special equipment such
as home oxygen, wheelchairs, and home ventilators
in addition to hospitalization and surgery; patients
with special equipment or selected surgeries were
regarded as having severe COPD.
Regression Models
A generalized linear model (GLM) was constructed
for each condition to estimate costs for the anemic
and nonanemic populations adjusting for demo-
graphics and measures of severity/comorbidity. The
difference in adjusted costs between the two popu-
lations was a proxy for the impact of anemia. All six
disease models included the following adjusting fac-
tors: age, sex, region of residency, insurance type,
disease severity, Charlson comorbidity index (CCI),
and whether patients had more than one of the
selected conditions. Disease severity was converted
into a dichotomous variable because of small sam-
ple sizes in the moderate and severe categories. In
each regression model, only the severity level for the
particular disease modeled was included. The CCI
deﬁnes 17 categories of comorbid conditions using
ICD-9 diagnosis codes [13]. Separate adjusted cost
models were created for direct and indirect costs. A
total of 12 separate models were created (i.e., six
conditions with two models per condition: one for
direct costs and one for indirect costs).
Budget Impact Model
A budget impact model was constructed to estimate
total anemia impact for these six conditions in a
deﬁned population. The budget impact model eval-
uated the total impact based on the population size,
the prevalence rates of the six diseases, the propor-
tions of anemic patients within each of these dis-
eases, and the difference between the adjusted
anemic and nonanemic costs. We assumed that the
estimated budget impact is representative of a pop-
ulation with similar sociodemographic characteris-
tics to that from the data sources.
Statistical Analysis
Distribution  of  the  data  and  model ﬁt. Various
methods were considered to adjust for the baseline
differences between the anemia and nonanemia
populations. Examples include propensity scores,
matching, and simply entering the adjusting varia-
bles in the model. A model form was chosen that
included the adjusting factors as independent vari-
ables. No additional advantage was foreseen from
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using other methods because the study was con-
ducted with a large enough sample size to include
each adjuster in the model.
The skewness and kurtosis of normality tests
rejected normality of the data for outcome measures
for both direct and indirect costs. A GLM was
selected over transformation of data because of
problems related to the resulting heteroscedasticity
of the data; the GLM was robust against distribu-
tional assumptions. The standard errors of the
model estimates were determined using a nonpara-
metric bootstrapping approach.
For comparative purposes, the model was also
ﬁt using ordinary least squares based on log-
transformed data. The ﬁt of either approach was
assessed using the adjusted R2 statistic, and it was
noticed that a higher value generally resulted from
the GLM approach.
Results
Study Patient Population
There were a total of 2,242,608 members with at
least 1 year of continuous enrollment during the
calendar years of 1999 to 2001. Among them,
123,037 patients had at least one of the six study
conditions. In this population, the prevalence rate
of COPD was approximately 2.13% (n = 47,837),
the highest among the six selected diseases, fol-
lowed by cancer (1.82%, n = 40,857), CHF
(0.58%, n = 13,041), RA (0.36%, n = 8009), IBD
(0.32%, n = 7200), and CKD (0.27%, n = 6093)
(Table 1). The total number of patients with the six
diseases constituted 5.49% of the study population
(n = 2,242,608). The study population was 58.8%
female, and overall there were a greater percentage
of females in the anemic than in the nonanemic pop-
ulation of each disease with the exception of COPD.
The mean age of the total population was 50.9
(±10.5) years old, but within each disease the mean
age of the anemic population was slightly higher
than that of the nonanemic population (Table 2).
Among the six disease populations, a total of
14,396 patients had anemia, which represented
0.64% of the total population in the data set. CKD
had the highest proportion of anemic patients,
followed by CHF, IBD, cancer, RA, and COPD
(Table 1). In addition, the CKD population had the
greatest proportion of patients that met the moder-
ate/severe criteria, followed by the cancer, IBD,
COPD, RA, and CHF populations.
Outcome Measures
Descriptive analyses for outcomes and adjusting
factors. Cross tabulation between disease severity
and cost demonstrated that the average cost for a
patient with mild disease severity was less than that
for a patient with moderate/high severity, with the
exception of CHF patients. In addition, as expected,
patients with moderate/high severity conditions had
a higher average number of hospitalizations per
year than did those with mild conditions, except for
CHF (Table 3). Cross tabulations for chemotherapy
by direct costs showed the expected observation
Table 1 Disease prevalence and anemia populations
Disease prevalence
in the study 
population*
Percent anemia 
(%) within 
disease population
Number 
of anemic
patients
Prevalence of anemia 
with disease among the
study population (%)
Cancer 0.0182 12.01 4,906 0.219
Chronic kidney disease 0.0027 26.10 1,590 0.0709
Chronic obstructive pulmonary disease 0.0213 6.89 3,295 0.147
Congestive heart failure 0.0058 21.25 2,771 0.124
Inﬂammatory bowel disease 0.0032 12.89 928 0.414
Rheumatoid arthritis 0.0036 11.31 906 0.0404
Total 0.0549 14,396 0.642
*Number of patients with the disease divided by the total number of patients in the data set (n = 2,242,608).
Table 2 Patient demographics
Cancer CKD RA IBD CHF COPD
Mean age (SD)
Overall 53.4 (8.7) 51.4 (10.3) 51.5 (9.2) 45.9 (11.5) 55.0 (8.5) 49.6 (11.2)
Anemic subgroup 53.6 (8.6) 52.74 (9.7) 51.8 (9.3) 46.9 (12.0) 55.4 (8.9) 52.4 (10.2)
Non-anemic subgroup 53.4 (8.7) 50.8 (10.5) 51.5 (9.2) 45.7 (11.5) 54.9 (8.4) 49.4 (11.3)
Female (%)
Overall 62.3 39.0 74.4 54.9 45.5 57.5
Anemia subgroup 64.9 50.8 80.2 63.8 51.9 37.2
Non-anemia subgroup 61.9 42.3 73.5 51.4 43.7 43.0
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that the patients who received these procedures
incurred higher costs (Table 4).
Direct costs. Unadjusted direct costs of the anemic
and nonanemic populations in each disease, and the
differences between unadjusted and adjusted costs,
are shown in Table 5. Among the six diseases, CKD
anemic patients incurred the greatest average
annual direct costs and the greatest unadjusted cost
difference between nonanemic and anemic patients.
The CHF and cancer anemic patients, respectively,
had the next highest direct costs and next greatest
unadjusted cost differences. After adjusting for
baseline characteristics including severity, the differ-
ence was reduced for all diseases; CHF patients
incurred the greatest adjusted cost difference, fol-
lowed by the CKD patients and the cancer patients
(Table 5).
Indirect  costs. The unadjusted indirect costs
incurred by anemic patients appeared to be very
Table 3 Average hospitalization and average direct cost by severity
Disease severity level Number of patients Number of hospitalizations per year* Direct cost† ($)
Cancer
Total patients 40,857
Mild 75.7% 0.43 16,717
Moderate/severe 24.3% 1.22 58,508
Chronic kidney disease
Total patients 6,093
Mild 58.8% 0.47 24,202
Moderate/severe 41.2% 2.24 85,145
Chronic obstructive pulmonary disease
Total patients 47,837
Mild 91.2% 0.32 10,658
Moderate/severe 8.8% 1.70 47,223
Congestive heart failure
Total patients 13,041
Mild 93.1% 1.34 40,650
Moderate/severe 7.0% 1.33 26,022
Inﬂammatory bowel disease
Total patients 7,200
Mild 89.1% 0.29 10,687
Moderate/severe 10.9% 1.50 37,925
Rheumatoid arthritis
Total patients 8,009
Mild 92.0% 0.21 10,780
Moderate/severe 8.0% 0.75 29,292
*Two sample t-test: P < 0.001 with exception of CHF (P = 0.7733).
†Two sample t-test: P < 0.001.
Table 4 Cancer costs and association with chemotherapy
No. patients Mean direct cost ($)
Chemotherapy
Total patients 40,857
Yes 1.9% 75,285
No 98.1% 25,967
Table 5 Adjusted and unadjusted direct/indirect costs per patient for the six study diseases
Disease
Unadjusted costs Difference in
unadjusted 
costs ($)
Difference in
adjusted  
costs ($)
Anemic 
population ($)
Non-anemic
population ($)
Direct costs
Cancer 60,447 21,807 38,640 18,418
Chronic kidney disease 78,209 24,784 53,425 20,529
Chronic obstructive pulmonary disease 37,462 11,549 25,913 8,979
Congestive heart failure 72,078 30,938 41,140 29,511
Inﬂammatory bowel disease 28,014 11,187 16,827 7,406
Rheumatoid arthritis 23,152 10,628 12,524 7,092
Total 299,362 110,893 188,469 91,935
Indirect costs
Cancer 3,389 2,907 482 108
Chronic kidney disease 2,948 2,992 -44 64
Chronic obstructive pulmonary disease 3,140 2,939 201 202
Congestive heart failure 3,293 3,231 62 -25
Inﬂammatory bowel disease 2,808 3,017 -209 -145
Rheumatoid arthritis 3,287 2,870 417 596
Total 18,192 17,273 919 800
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similar among the six conditions (Table 5). In the
CKD and IBD populations, nonanemic patients
incurred higher average annual costs than the ane-
mic patients. After adjusting for the baseline differ-
ences, the direction of the cost difference changed
for the CKD population but not for the IBD popu-
lation. As with CKD, the difference in the indirect
cost for CHF patients also changed its direction
after adjusting the baseline, but the change was
from the unadjusted cost being higher for the ane-
mic population to the adjusted cost being higher for
the nonanemic population.
Budget  impact  model. The budget impact model
was based on the prevalence rates of the six condi-
tions, the rates of anemia within conditions, and the
differences in adjusted costs from the current study
to obtain annual total anemia-associated costs in a
population. The model calculated the anemia-
associated costs within each condition and the total
costs for all six conditions for any given population
size.
The direct, indirect, and total costs associated
with anemia in each condition and across all six for
a hypothetical population of 1 million members are
shown in Table 6. The results showed that for 1 mil-
lion members, the total anemia-associated direct
costs would be $110,433,492, total indirect costs
would be $866,726, and the total of direct and indi-
rect costs would be $111,300,218. The anemia-
associated direct cost per member per month
(PMPM) would be $9.20 and the indirect cost
PMPM would be $0.07. The anemia-associated
direct cost per member per year (PMPY) would be
$110.43 and the indirect cost PMPY would be
$0.87.
Discussion
This study estimated the economic burden of ane-
mia within six chronic diseases (RA, IBD, COPD,
CKD, cancer, and CHF) in a typical managed care
population. Direct and indirect medical costs and
the incremental costs of anemia were analyzed.
After adjusting for differences in demographics, a
portion of condition severity, and comorbidity,
patients with anemia had high costs and anemic
patients had substantially higher costs than nonane-
mic patients. For a population of 1 million lives,
anemia-associated costs were estimated at $110
million for these six conditions.
As expected, anemic patients incurred higher
costs than nonanemic patients. The highest differ-
ences in cost between anemic and nonanemic
patients were observed among patients with CHF,
CKD, and cancer; their annual cost differences
ranged from $18,418 to $29,511 per patient. Our
study also highlighted important differences in the
indirect costs of anemia, measured as work produc-
tivity. In general, the indirect costs were signiﬁcantly
less than the direct medical costs attributed to ane-
mia. In this study, anemia had an impact on work
productivity among the cancer, RA, and COPD
patients.
The prevalence rates for each condition in this
analysis were lower than what has been reported
in other studies (NHANES data reported rates of
3.67% for cancer, 3.58% for CKD, 3.45% for
RA, 2.13% for CHF, and 13.6% for COPD) [14].
The prevalence of anemia in each condition has
been examined in various studies. The European
Cancer Anemia Survey (ECAS) reported that 39%
of the cancer patients surveyed had anemia [15].
One study found that 47.7% of 5222 predialysis
patients had anemia [16]. A meta-analysis
reported a 33%-60% prevalence range for mild
anemia in RA [8]. A review reported that the prev-
alence of anemia in CHF patients ranged from 4%
to 55% depending on the population studied [17],
and several other studies conducted in countries
such as the UK and Canada reported different
rates for the prevalence of anemia in CHF popula-
tions (34%, 10%-20%, and 17%) [18–20]. More-
over, a meta-analysis found that the prevalence of
Table 6 Budget impact model for a hypothetical population of one million members of similar population
Disease
Anemia associated
direct costs ($)
Anemia associated
indirect costs ($)
Total anemia  
associated costs ($)
Cancer 40,292,607 282,245 40,574,852
Chronic kidney disease 14,554,978 45,871 14,600,849
Chronic obstructive pulmonary disease 13,192,085 294,896 13,486,981
Congestive heart failure 36,464,196 -19,853 36,464,196
Inﬂammatory bowel disease 3,064,528 -44,942 3,064,528
Rheumatoid arthritis 2,865,098 243,713 3,108,811
Total across 6 diseases 110,433,492 866,726 111,300,218
Per member per month 9.20 0.07 9.28
Per member per year 110.43 0.87 111.30
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anemia in the IBS population ranged from 8.8%
to 73.7%, depending on the patient subpopulation
[7]. The main reasons suggested for the observed
variations in the rates were the differences among
the study populations and how people deﬁne ane-
mia. Similar to previous studies, the differences in
rates within the current study could be attributed
to the current study population selection criteria,
which were more restrictive than in prior work.
The data for this study were from an insured pop-
ulation and entry criteria required that patients
visit a physician and have one of the speciﬁed
diagnostic codes for the six conditions of interest.
In addition, the low rates may be attributed to the
fact that the majority of the insured population in
the database was still in the working force; thus
the study population was relatively young. Despite
these reasons for the low anemia prevalence
observed, our study objective was to investigate
the economic impact of anemia, and the individu-
als included here were shown to have a substantial
economic burden.
Although patients with anemia were observed to
have higher costs than nonanemic patients with the
same condition, it could be questioned whether
these costs can be truly attributed to the anemia or
rather from the underlying condition severity.
Patients with anemia are likely to be sicker than
their nonanemic counterparts; with this in mind,
various adjustment factors were included in the
analysis. Attention was focused on deﬁning disease
severity as an important adjuster: severity was
based on ICD-9 diagnostic codes, selected CPT
codes, certain medications as indicators of sicker
patients, durable medical equipment codes, and evi-
dence of hospitalization. In addition to disease
severity, the adjustment included two measures of
comorbidity: the CCI and a measure of the number
of anemia-associated conditions present for each
patient. Results showed that the severity adjustment
signiﬁcantly lowered the differences between the
anemic and nonanemic populations for each dis-
ease; the adjusted differences in cost between the
anemic and nonanemic patients ranged from one-
half to two-thirds of the unadjusted differences in
cost.
In addition, several steps were completed to test
the case mix adjustment. Cross-tabulations between
hospitalization and cost, cost and severity, hospital-
ization and severity, and chemotherapy and cost
were each performed. Results showed that the
adjustment process captured important differences.
Even with the adjustment, differences in costs
between anemic and nonanemic patients remained
larger than expected. Analyses based on administra-
tive data always have limitations in the depth of
clinical information. Given the inability to fully
account for differences in case mix, the estimates
should be viewed cautiously and as an upper
bound.
Other limitations should be noted. Ascertain-
ment bias may have existed in which high-utilizing
patients were more likely to be “labeled” anemic,
because they visited the doctor more often, than
low-utilizing patients who had less opportunity to
have anemia identiﬁed. This may be an explanation
for the relatively low prevalence rates of anemia in
our study population as compared with study pop-
ulations in prior work such as the ECAS [15]. Based
on this theory, our study sample may be more likely
to select for moderate-to-severe anemia and not
include anemic patients who had low health-care
resource utilization. As a result, the difference
between patients with anemia and without anemia
could have been overestimated. Nevertheless, the
extent of ascertainment bias in this study was difﬁ-
cult to evaluate because prior studies have been
reporting various rates of anemia prevalence in dif-
ferent study populations. It is therefore more valid
to consider these results to be higher-end per-patient
cost estimates. Finally, we used ICD-9 diagnostic
codes to identify the anemic patients. Although in
many instances we ascertained that the patient had
undergone laboratory testing (e.g., hematocrit and
hemoglobin), the administrative database did not
have the results of the testing so validation or
severity stratiﬁcation of the anemia could not be
performed.
These limitations should not undermine the fact
that patients with diagnostic designations of anemia
are costly and should be of concern. How much of
the incremental cost of anemia is due to unmeas-
ured severity cannot be known for sure, but what is
known is that patients with anemia consume a sig-
niﬁcant amount of health-care resources. For that
reason alone, closer examination of this population
would be important. Annual total anemia-associ-
ated costs in our simulated population of 1 million
patients were high ($111,300,218). Moreover, data
are now becoming clearer that treatment of anemia
can improve quality of life [21]. For clinical and
economic reasons, those responsible for the care of
populations should be concerned about patients
with anemia. What remains unanswered is whether
identiﬁcation and management of anemia can
reduce the economic burden in these patients. Fur-
ther research is needed to answer this important
policy question.
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Appendix 1
Disease severity criteria
Disease Severity Severity criteria
Cancer Moderate Active chemotherapy
Severe 1. Metastatic disease diagnosis (196.0–199.0)
or
2. Any of the following combinations:
a) Lung cancer (162.x) + liver cancer (155.x)/brain cancer (191.x)
b) Breast cancer (174.x) + lung cancer (162.x)/brain cancer (191.x)/liver cancer (155.x)
c) Prostate cancer (185.x) + bone cancer (170.x)
d) Colon cancer (154.x) + lung cancer (162.x)/liver cancer (155.x)
Chronic kidney 
disease (CKD)
Mild No hospitalization for CKD
Moderate One hospitalization for CKD
Severe 1. Two or more hospitalizations for CKD per year
or
2. Kidney transplant surgery during a 1-year period V42.0, 996.81
Rheumatoid 
arthritis (RA)
Mild Less expensive nonbiologic drugs (i.e., average monthly costs treatment with lowest recommended
dosage is < $200)
a) NSAIDs: Acetylated salicylates: aspirin (Anacin, Ascriptin, Bayer, Bufferin, Ecotrin, Excedrin tablets)
b) Nonacetylated salicylates: choline and magnesium trisalicylates (CMT, Tricosal, Trilisate); sodium 
salicylate (only available as generic); salicylsalicylic acid/salsalate (Amigesic, Anaﬂex 750, Disalcid, 
Marthritic, Mono-Gesic, Salﬂex, Salsitab) 
Cox-2 Inhibitors: celecoxib (Celebrex); rofecoxib (Vioxx); valdecoxib (Bextra)
Other NSAIDs: Diclofenac (Voltaren, Voltaren XR, Arthrotec); diﬂunisal (Dolobid); etodolac (Lodine, 
Lodine XL); fenoprofen (Nalfon); ﬂurbiprofen (Ansaid); ibuprofen (Motrin, Advil, Motrin IB, Nuprin) 
indomethacin (Indocin, Indocin SR); ketoprofen (Orudis, Oruvail, Actron, Orudis KT); meclofenamate 
sodium (Meclomen); mefenamic acid (Ponstel); meloxicam (Mobic); nabumetone (Relafen); naproxen 
(Naprosyn, EC-Naprosyn; Naprelan); naproxen sodium (Anaprox, Aleve); oxaprozin (Daypro); piroxicam 
(Feldene); sulindac (Clinoril); tolmetin (Tolectin)
c) DMARDs: hydroxychloroquine sulfate (Plaquenil); sulfasalazine (Azulﬁdine, Azulﬁdine En-tabs); 
methotrexate (Rheumatrex, Trexall); gold sodium thiomalate (Myochrysine); auranoﬁn (Ridaura); 
azathioprine (Imuran); minocycline (Minocin); penicillamine (Cuprimine, Depen)
Moderate 1. Expensive biologic therapy (Enbrel, Remicade, Kineret); etanercept (Enbrel): J1438 (*injectable when 
not self-administered); inﬂiximab (Remicade): J1745; anakinra (Kineret):
or
2. Expensive nonbiologic therapy (Arava, Cyclosporinee); leﬂunomide (Arava); cyclosporinee 
(Sandimmune); cyclosporinee (Neoral)
Severe Any joint surgery (Refer to orthopedic RA codes)
Inﬂammatory 
bowel disease
(IBD)
Mild No claim for any drugs in the “Moderate” and “Severe” categories
Moderate Any of the following drugs:
a) Aminosalicylates: sulfasalazine (Azulﬁdine); mesalamine (Rowasa, Salofalk, Claversal, Pentasa, Asacol, 
Colazide); balsalazide (Colazal); olsalazine (Dipentum);
b) Antimicrobials: metronidazole (Flagyl); Immunosuppressants: cyclosporine (Sandimmune, Neoral)
c) Oral steroids: hydrocortisone (oral) (Cortisol, Cortef); prednisolone; prednisone (Deltasone); 
dexamethasone (Decadron)
Severe Inﬂiximab (Remicade); azathioprine (Imuran), mercaptopurine (Purinethol);
or
Surgery or evidence of past surgery: procedure codes for enterectomy, colectomy, proctectomy, 
enterostomy, ileostomy, colostomy and diagnosis codes V44.2 (ileostomy status) and V44.3 (colostomy 
status)
or
Two or more hospitalizations with IBD diagnosis (ICD-9 code = 558.9) during the 1-year period
Congestive heart Mild 1. Ofﬁce visits only for CHF (No hospitalization)
failure (CHF) or
2. Taking 1–2 CHF medication(s) without any hospitalization during the 1-year period
Moderate 1. One hospitalization for CHF during the 1-year period
or
2. Concurrently taking at least 3 CHF medications for at least 3 months without any hospitalization during 
the 1-year period
(continued)
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Severe 1. Multiple hospitalizations for CHF during a 1-year period
or
2. Concurrently taking 4 or 5 classes of CHF medications for at least 3 months regardless of 
hospitalization during the year 
Seven classes of medications for CHF:
a) Loop diuretics: bumetanide (Bumex); furosemide (Lasix); torsemide (Demadex)
b) Beta-blockers: bisoprolol (Zebeta); carvedilol (Coreg); metoprolol (Lopressor and Toprol-XL);
c) ACE-Is: benazepril (Lotensin); captopril (Capoten); enalapril (Vasotec); fosinopril (Monopril); lisinopril 
(Prinivil and Zestril); moexipril (Univasc); perindopril (Aceon); quinapril (Accupril); ramipril (Altace); 
trandolapril (Mavik)
d) ARBs: Candesartan cilexetil (Atacand); Eprosartan (Teveten); irbesartan (Avapro); losartan (Cozaar); 
olmesartan (Benicar); telmisartan (Micardis); valsaratan (Diovan)
e) Digitalis glycosides: digoxin (Lanoxin)
f) Vasodilators: hydralazine hydrochloride (Hydrazaline), isosorbide dinitrate
g) Aldosterone-receptor inhibitor: spironolactone (Aldactone)
Chronic obstructive
pulmonary disease 
(COPD)
Moderate One hospitalization or 2 ER visits/year with diagnosis of Acute respiratory failure (518.81) with COPD
or
Pneumonia (486) with COPD
or
Chronic respiratory failure: 518.83, 518.84
Severe 1. Two or more hospitalizations, or three or more ER visits/year with diagnosis of
a) COPD
or
b) Acute respiratory failure (518.81)
or
c) Pneumonia (486)
or
d) Chronic respiratory failure: 518.83, 518.84
or
2. DME and wheelchair utilization (E0950-E1298, K0001-K0108) (USE HCPCS codes)
a) Codes for oxygen (A0422, A7018, E1390, A4611-A4627E1353, A4616, E1405, E1406)
b) Codes for equipment related to oxygen (A4620, A4621, E1355, A4611-A4627, E0424-E0480, E0425-
E0444, E0455)
c) Codes for any home ventilator (A4611-A4613, A4483, E0460, E0450)
or
3. Tracheostomy codes: 519.0x or V44.0
or
4. Chronic pulmonary heart disease/lung disease code: 416.x
Disease Severity Severity criteria
The criterion of hospitalization indicated whether the study patients had an inpatient hospital stay, not including length of hospital stay.
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